© Reuters
Analysts from BMO Capital Markets have identified Eli Lilly & Co (NYSE:). as the most likely pharmaceutical leader in the rapidly growing U.S. obesity drug market into the 2030s, according to a report published on Friday. Despite facing fierce competition from Novo Nordisk (NYSE:), the producer of Ozempic and Wegovy, Eli Lilly’s diverse and effective product range is expected to provide a competitive edge.
Eli Lilly’s portfolio includes orforglipron, an oral medication, tirzepatide, an injectable drug, and retatrutide, a next-generation treatment. The company’s strategic investments in manufacturing and planning for branded rollouts are anticipated to solidify its position in the market.
The report also underscored the significant potential for growth in the obesity drug market both domestically and internationally. Analysts forecast that global sales for these drugs will reach an impressive $100 billion by 2035.
Despite recent downturns in shares of leading companies in the obesity drug market, Eli Lilly’s shares demonstrated resilience. On Friday morning trading, shares were up 0.5%, marking a 50% increase since the start of the year. Novo Nordisk has also experienced substantial growth with its shares up 1% in premarket trading and a total increase of 35% year-to-date.
BMO Capital Markets analysts maintain an “outperform” rating on Eli Lilly’s shares and set a target price at $633. This prediction comes amidst ongoing market fluctuations and emphasizes the analysts’ confidence in Eli Lilly’s potential dominance in the obesity drug sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
